임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
45건 표시
- 1상모집 중단 (진행 중)· HealthyA Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)
리드: 머크(MSD)
- 1상모집 중단 (진행 중)· HealthyA Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)
리드: 머크(MSD)
- 1상모집 중단 (진행 중)· MelanomaA Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Lung CancerOncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Neoplasm MetastasisA Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
리드: 머크(MSD)
- 1상모집 중단 (진행 중)· Non-small Cell Lung CancerSacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
리드: 머크(MSD)
- 1상모집 중단 (진행 중)· Metastatic Solid TumorsStudy of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
리드: 머크(MSD)
- 1상모집 중단 (진행 중)· Advanced CancerPOTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Advanced or Metastatic Solid TumorsA Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· AstrocytomaStudy of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Solid TumorA Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Advanced or Metastatic Solid TumorsA Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
리드: 머크(MSD)
- 1상모집 중단 (진행 중)· Hematological MalignanciesA Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
리드: 머크(MSD)
- 1상모집 중단 (진행 중)· Metastatic Solid TumorDose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Pancreatic CancerStudy of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Advanced CancerASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· PTCLStudy of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Neurofibromatosis Type 1Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
리드: 아스트라제네카 · 협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Non-Small Cell Lung Cancer (NSCLC)HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
협력: 아스트라제네카, 머크(MSD)
- 1상모집 중단 (진행 중)· Renal Cell CarcinomaA Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Neurofibromatosis 1A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
리드: 아스트라제네카 · 협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Advanced CancerFS120 Phase 1/1b Study in Patients With Advanced Malignancies
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Advanced or Metastatic NSCLCDatopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Endometrial CancerFrontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Breast CancerDS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
협력: 아스트라제네카, 머크(MSD)
- 1상모집 중단 (진행 중)· Recurrent GlioblastomaPembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Lung Non-Small Cell CarcinomaCCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Breast Cancer MetastaticOlaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
협력: 아스트라제네카, 머크(MSD)
- 1상모집 중단 (진행 중)· Bladder Small Cell Neuroendocrine CarcinomaPembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Malignant Neoplasm of BreastPembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Advanced MelanomaA Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Triple Negative Breast CancerPVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Non-Small Cell Lung Cancer (NSCLC)U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Solid TumorsSafety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
리드: 모더나 · 협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Non Small Cell Lung CancerCombination Study of Guadecitabine/ASTX727 and Pembrolizumab
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Non Small Cell Lung CancerA Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
리드: 일라이 릴리 · 협력: 머크(MSD)
- 1상모집 중단 (진행 중)· Invasive Bladder CancerPembrolizumab in Muscle Invasive/Metastatic Bladder Cancer
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· GlioblastomaPersonalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
협력: 머크(MSD)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.